BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.50 Consensus PT from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has earned an average rating of "Moderate Buy" from the six research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $15.50.

BCRX has been the topic of several recent analyst reports. Royal Bank of Canada reissued an "outperform" rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Evercore ISI lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. Needham & Company LLC upped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Monday, January 13th. Barclays raised their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 5th. Finally, JMP Securities reissued a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $33,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of BioCryst Pharmaceuticals by 3.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company's stock worth $3,016,000 after buying an additional 11,581 shares during the last quarter. Woodline Partners LP bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at about $3,385,000. Two Sigma Advisers LP increased its position in shares of BioCryst Pharmaceuticals by 14.6% in the fourth quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock valued at $18,799,000 after acquiring an additional 318,800 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in BioCryst Pharmaceuticals by 0.8% during the fourth quarter. Two Sigma Investments LP now owns 1,774,214 shares of the biotechnology company's stock worth $13,342,000 after acquiring an additional 13,406 shares in the last quarter. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Performance

BCRX stock remained flat at $9.39 during midday trading on Monday. 3,415,358 shares of the company's stock were exchanged, compared to its average volume of 2,822,243. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $9.50. The stock's 50 day moving average price is $7.94 and its 200-day moving average price is $7.81. The stock has a market capitalization of $1.94 billion, a PE ratio of -15.39 and a beta of 1.75.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.